Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arzoxifene for prevention of vertebral fractures and invasive breast cancer in postmenopausal women
2004-001562-41Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in osteoporosis, low bone mineral density and breast cancer comparing Arzoxifene with Placebo (2 arms). Primary endpoints: Incidence of new vertebral fractures and Incidence of invasive breast cancer. Started Apr 2010; status: completed.
02
Drugs
arzoxifene
03
Conditions
osteoporosislow bone mineral densitybreast cancer
Beyond the preview
Go deeper on 2004-001562-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001562-41.